To establish platelet function and primary hemostasis during lung transplantation
ID
Source
Brief title
Condition
- Respiratory disorders NEC
- Respiratory tract therapeutic procedures
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
The development of functional properties of primary hemostasis (especially of
platelets and vWF) during lung transplantation. The appearance of (partly)
activated circulating platelets during lung transplantation, especially after
reperfusion of the graft.
Secondary outcome
none
Background summary
Blood platelets play a pivotal role in primary hemostasis, but other
potentially harmful effects of platelets have also been described. We are
studying the effect of platelets and platelet-graft interaction in liver
transplantation but like to extend this study to lung transplantation
recipients for two reasons. First, the development of the hemostatic system
during lung transplantation and potentially occurring hemostatic changes which
can contribute to bleeding complications during the procedure is incompletely
known. In contrast to liver transplant recipients, lung transplant patients
have a relatively normal hemostatic system at the start of surgery, and
therefore a comparison between these two patient groups is of interest. Second,
we aim to investigate whether the platelet-graft interaction after reperfusion
is not restricted to liver transplantation but also occurs in pulmonary
transplant procedures, and whether a similar mechanism is responsible.
Study objective
To establish platelet function and primary hemostasis during lung
transplantation
Study design
Clinical observational mono-center study.
Study burden and risks
During and after lungtransplantatie or cardiac surgery at different timepoint,
different bloodsamples will be withdrawn. After surgery at two different days,
postoperative day 1 and 5, some extra bloodsamples will be taken next to the
regulary blood samples taken. No extra outpatient visit are needed for this
project. After 5 days the research will end. The risks for the patient when
participating in this study will be neglectable.
Hanzeplein 1
9713 GZ Groningen
Nederland
Hanzeplein 1
9713 GZ Groningen
Nederland
Listed location countries
Age
Inclusion criteria
Age >= 18 years
First bilateral lungtransplantation (study population), planned off-pump.
Off-pump coronary artery bypass grafting (control group)
Non-inflammatory disease
Informed consent
Exclusion criteria
Combined organ transplantations
Use of pre-operative antiplatelet medication
Peroperative use of CPB
Peroperative transfusion of platelet concentrates
Inflammatory diseases (e.g. cystic fibrosis)
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| CCMO | NL21717.042.08 |